Bone Marrow Derived Macrophages, NSCLC cell lines, and Kras G12D Lung Tumors Treated with Epigenetic Agents

Transcriptional profiling of Aza+ITF-2357 treated bone marrow derived macrophages vs. Mock treated bone marrow derived macrophages. Aim was to elucidate the effects of epigentic drug treatment on in vitro cultured macrophages and to compare these data to in vivo treated macrophage populations. Transcriptional profiling of NSCLC cell lines treated with epigenetic agents Transcriptional profiling of immune populations in the lung Kras G12D tumor micronevironment treated with combination epigenetic therapy Transcriptional profiling of lung Kras G12D tumors treated with combination epigenetic therapy Two color array representation of two-condition experiment Aza+ITF-2357 treated bone marrow derived macrophages vs. Mock treated bone marrow derived macrophages. Data are single array representation of 3 pooled bone marrow derived macrophage replicates for each condition. Two-condition experiment, Mock vs. MS-275, Mock vs. ITF-2357, Mock vs. Azacitidine, Mock vs. Azacitidine+MS-275, Mock vs. Azacitidine+ITF-2357 Two-condition experiment: Mock vs. 0.5mg/kg Azacitidine + 2.0mg/kg ITF-2357. Populations assayed in this experiment: Macrophages- CD45+, CD11b+, F4/80+; T lymphocytes: CD45+, CD3+, CD8+ Two-condition experiment, Mock vs. 0.5mg/kg Azacitidine + 2.0mg/kg ITF-2357